nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.551	0.708	CbGbCtD
Vemurafenib—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.227	0.292	CbGbCtD
Vemurafenib—VIIth nerve paralysis—Riluzole—amyotrophic lateral sclerosis	0.00839	0.0946	CcSEcCtD
Vemurafenib—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00566	0.0638	CcSEcCtD
Vemurafenib—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00515	0.0581	CcSEcCtD
Vemurafenib—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00418	0.0472	CcSEcCtD
Vemurafenib—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00311	0.0351	CcSEcCtD
Vemurafenib—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00284	0.0321	CcSEcCtD
Vemurafenib—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00264	0.0297	CcSEcCtD
Vemurafenib—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00257	0.029	CcSEcCtD
Vemurafenib—Etoricoxib—PTGS2—amyotrophic lateral sclerosis	0.00201	1	CrCbGaD
Vemurafenib—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00197	0.0222	CcSEcCtD
Vemurafenib—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00195	0.022	CcSEcCtD
Vemurafenib—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00192	0.0217	CcSEcCtD
Vemurafenib—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00192	0.0217	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00189	0.0213	CcSEcCtD
Vemurafenib—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.0017	0.0192	CcSEcCtD
Vemurafenib—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.0017	0.0191	CcSEcCtD
Vemurafenib—RAF1—hindbrain—amyotrophic lateral sclerosis	0.0017	0.136	CbGeAlD
Vemurafenib—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00163	0.0184	CcSEcCtD
Vemurafenib—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00161	0.0182	CcSEcCtD
Vemurafenib—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.0016	0.0181	CcSEcCtD
Vemurafenib—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00157	0.0177	CcSEcCtD
Vemurafenib—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00156	0.0176	CcSEcCtD
Vemurafenib—Chills—Riluzole—amyotrophic lateral sclerosis	0.00155	0.0175	CcSEcCtD
Vemurafenib—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00153	0.0172	CcSEcCtD
Vemurafenib—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.0015	0.017	CcSEcCtD
Vemurafenib—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00147	0.0166	CcSEcCtD
Vemurafenib—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00145	0.0164	CcSEcCtD
Vemurafenib—Cough—Riluzole—amyotrophic lateral sclerosis	0.00131	0.0148	CcSEcCtD
Vemurafenib—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00128	0.0144	CcSEcCtD
Vemurafenib—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00128	0.0144	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00127	0.0143	CcSEcCtD
Vemurafenib—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00123	0.0138	CcSEcCtD
Vemurafenib—Infection—Riluzole—amyotrophic lateral sclerosis	0.00122	0.0138	CcSEcCtD
Vemurafenib—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.0012	0.0136	CcSEcCtD
Vemurafenib—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00119	0.0134	CcSEcCtD
Vemurafenib—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00115	0.0129	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00112	0.0126	CcSEcCtD
Vemurafenib—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00107	0.012	CcSEcCtD
Vemurafenib—RAF1—embryo—amyotrophic lateral sclerosis	0.00106	0.0854	CbGeAlD
Vemurafenib—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00106	0.012	CcSEcCtD
Vemurafenib—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00106	0.0119	CcSEcCtD
Vemurafenib—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00105	0.0118	CcSEcCtD
Vemurafenib—RAF1—brainstem—amyotrophic lateral sclerosis	0.000972	0.0782	CbGeAlD
Vemurafenib—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00097	0.0109	CcSEcCtD
Vemurafenib—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000904	0.0102	CcSEcCtD
Vemurafenib—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000881	0.00993	CcSEcCtD
Vemurafenib—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000868	0.0098	CcSEcCtD
Vemurafenib—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00084	0.00947	CcSEcCtD
Vemurafenib—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000812	0.00916	CcSEcCtD
Vemurafenib—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00078	0.0088	CcSEcCtD
Vemurafenib—Rash—Riluzole—amyotrophic lateral sclerosis	0.000774	0.00873	CcSEcCtD
Vemurafenib—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000773	0.00872	CcSEcCtD
Vemurafenib—Headache—Riluzole—amyotrophic lateral sclerosis	0.000769	0.00867	CcSEcCtD
Vemurafenib—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000729	0.00822	CcSEcCtD
Vemurafenib—BRAF—cerebellum—amyotrophic lateral sclerosis	0.000719	0.0579	CbGeAlD
Vemurafenib—RAF1—medulla oblongata—amyotrophic lateral sclerosis	0.000677	0.0545	CbGeAlD
Vemurafenib—RAF1—spinal cord—amyotrophic lateral sclerosis	0.000604	0.0486	CbGeAlD
Vemurafenib—BRAF—brain—amyotrophic lateral sclerosis	0.000584	0.047	CbGeAlD
Vemurafenib—RAF1—nervous system—amyotrophic lateral sclerosis	0.000509	0.041	CbGeAlD
Vemurafenib—RAF1—central nervous system—amyotrophic lateral sclerosis	0.00049	0.0395	CbGeAlD
Vemurafenib—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000481	0.0387	CbGeAlD
Vemurafenib—RAF1—cerebellum—amyotrophic lateral sclerosis	0.000479	0.0386	CbGeAlD
Vemurafenib—ORM1—spinal cord—amyotrophic lateral sclerosis	0.000417	0.0336	CbGeAlD
Vemurafenib—RAF1—brain—amyotrophic lateral sclerosis	0.000389	0.0313	CbGeAlD
Vemurafenib—ORM1—nervous system—amyotrophic lateral sclerosis	0.000351	0.0283	CbGeAlD
Vemurafenib—ORM1—central nervous system—amyotrophic lateral sclerosis	0.000338	0.0272	CbGeAlD
Vemurafenib—ABCG2—medulla oblongata—amyotrophic lateral sclerosis	0.00028	0.0226	CbGeAlD
Vemurafenib—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000275	0.0222	CbGeAlD
Vemurafenib—ABCG2—spinal cord—amyotrophic lateral sclerosis	0.00025	0.0201	CbGeAlD
Vemurafenib—ABCC1—cerebellum—amyotrophic lateral sclerosis	0.000239	0.0193	CbGeAlD
Vemurafenib—ALB—brain—amyotrophic lateral sclerosis	0.000236	0.019	CbGeAlD
Vemurafenib—ABCG2—cerebellum—amyotrophic lateral sclerosis	0.000198	0.016	CbGeAlD
Vemurafenib—ABCC1—brain—amyotrophic lateral sclerosis	0.000194	0.0157	CbGeAlD
Vemurafenib—ABCG2—brain—amyotrophic lateral sclerosis	0.000161	0.013	CbGeAlD
Vemurafenib—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000147	0.0118	CbGeAlD
Vemurafenib—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000144	0.0116	CbGeAlD
Vemurafenib—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000141	0.0114	CbGeAlD
Vemurafenib—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000139	0.0112	CbGeAlD
Vemurafenib—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000136	0.0109	CbGeAlD
Vemurafenib—ABCC1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000119	0.00101	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000117	0.000983	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000117	0.000983	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000116	0.000974	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000116	0.000974	CbGpPWpGaD
Vemurafenib—RAF1—Oncostatin M Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000115	0.000972	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000115	0.000967	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000115	0.000967	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000115	0.000966	CbGpPWpGaD
Vemurafenib—BRAF—Senescence and Autophagy in Cancer—TP53—amyotrophic lateral sclerosis	0.000114	0.000957	CbGpPWpGaD
Vemurafenib—BRAF—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000112	0.000947	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—ERBB4—amyotrophic lateral sclerosis	0.000112	0.000942	CbGpPWpGaD
Vemurafenib—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000112	0.000939	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000111	0.000937	CbGpPWpGaD
Vemurafenib—BRAF—Disease—VCP—amyotrophic lateral sclerosis	0.000111	0.000935	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000111	0.000935	CbGpPWpGaD
Vemurafenib—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.000111	0.000931	CbGpPWpGaD
Vemurafenib—CYP2D6—brain—amyotrophic lateral sclerosis	0.00011	0.00888	CbGeAlD
Vemurafenib—ALB—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.00011	0.000928	CbGpPWpGaD
Vemurafenib—ALB—Platelet degranulation—IGF1—amyotrophic lateral sclerosis	0.000107	0.000898	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000105	0.000885	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000104	0.000879	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000104	0.000876	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000103	0.000868	CbGpPWpGaD
Vemurafenib—RAF1—VEGFA-VEGFR2 Pathway—VEGFA—amyotrophic lateral sclerosis	0.000102	0.000863	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000102	0.000857	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000102	0.000857	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000102	0.000857	CbGpPWpGaD
Vemurafenib—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—amyotrophic lateral sclerosis	0.000102	0.000855	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—IGF1—amyotrophic lateral sclerosis	9.91e-05	0.000835	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	9.87e-05	0.000831	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—SACM1L—amyotrophic lateral sclerosis	9.76e-05	0.000822	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by VEGF—VEGFA—amyotrophic lateral sclerosis	9.68e-05	0.000815	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	9.62e-05	0.000811	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways in Glioblastoma—TP53—amyotrophic lateral sclerosis	9.58e-05	0.000807	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CHMP2B—amyotrophic lateral sclerosis	9.52e-05	0.000802	CbGpPWpGaD
Vemurafenib—RAF1—BDNF signaling pathway—CASP3—amyotrophic lateral sclerosis	9.52e-05	0.000802	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	9.46e-05	0.000797	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CHMP2B—amyotrophic lateral sclerosis	9.44e-05	0.000795	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—DAO—amyotrophic lateral sclerosis	9.44e-05	0.000795	CbGpPWpGaD
Vemurafenib—BRAF—Focal Adhesion—VEGFA—amyotrophic lateral sclerosis	9.36e-05	0.000788	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	9.18e-05	0.000773	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—FIG4—amyotrophic lateral sclerosis	9.18e-05	0.000773	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—MMP9—amyotrophic lateral sclerosis	9.15e-05	0.000771	CbGpPWpGaD
Vemurafenib—RAF1—Retinoblastoma (RB) in Cancer—TP53—amyotrophic lateral sclerosis	9.14e-05	0.00077	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	9.07e-05	0.000764	CbGpPWpGaD
Vemurafenib—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	9e-05	0.000758	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	8.9e-05	0.000749	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	8.78e-05	0.00074	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	8.72e-05	0.000734	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	8.72e-05	0.000734	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PLB1—amyotrophic lateral sclerosis	8.61e-05	0.000725	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PLB1—amyotrophic lateral sclerosis	8.54e-05	0.000719	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—RAB5A—amyotrophic lateral sclerosis	8.53e-05	0.000719	CbGpPWpGaD
Vemurafenib—BRAF—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	8.5e-05	0.000716	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	8.42e-05	0.000709	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—DAO—amyotrophic lateral sclerosis	8.3e-05	0.000699	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PFN1—amyotrophic lateral sclerosis	8.27e-05	0.000696	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	8.2e-05	0.00069	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	8.19e-05	0.00069	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	8.19e-05	0.000689	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CST3—amyotrophic lateral sclerosis	7.96e-05	0.000671	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	7.95e-05	0.00067	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—TP53—amyotrophic lateral sclerosis	7.86e-05	0.000662	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—ATF1—amyotrophic lateral sclerosis	7.82e-05	0.000659	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	7.8e-05	0.000657	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VCP—amyotrophic lateral sclerosis	7.77e-05	0.000654	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	7.75e-05	0.000653	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	7.74e-05	0.000652	CbGpPWpGaD
Vemurafenib—RAF1—Disease—VCP—amyotrophic lateral sclerosis	7.68e-05	0.000647	CbGpPWpGaD
Vemurafenib—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	7.63e-05	0.000643	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—VCP—amyotrophic lateral sclerosis	7.61e-05	0.000641	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—DCTN1—amyotrophic lateral sclerosis	7.61e-05	0.00064	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	7.6e-05	0.00064	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	7.58e-05	0.000638	CbGpPWpGaD
Vemurafenib—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	7.53e-05	0.000634	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	7.53e-05	0.000634	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CASP9—amyotrophic lateral sclerosis	7.45e-05	0.000627	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—SOD1—amyotrophic lateral sclerosis	7.42e-05	0.000625	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	7.39e-05	0.000622	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	7.15e-05	0.000602	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PLB1—amyotrophic lateral sclerosis	7.15e-05	0.000602	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—VAPB—amyotrophic lateral sclerosis	7.09e-05	0.000597	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—TPK1—amyotrophic lateral sclerosis	7.09e-05	0.000597	CbGpPWpGaD
Vemurafenib—ALB—Platelet degranulation—VEGFA—amyotrophic lateral sclerosis	6.96e-05	0.000586	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	6.95e-05	0.000586	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	6.68e-05	0.000563	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	6.66e-05	0.000561	CbGpPWpGaD
Vemurafenib—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—amyotrophic lateral sclerosis	6.63e-05	0.000559	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	6.61e-05	0.000556	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	6.61e-05	0.000556	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GSR—amyotrophic lateral sclerosis	6.6e-05	0.000556	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—TP53—amyotrophic lateral sclerosis	6.55e-05	0.000551	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—VAPA—amyotrophic lateral sclerosis	6.48e-05	0.000546	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—VEGFA—amyotrophic lateral sclerosis	6.47e-05	0.000545	CbGpPWpGaD
Vemurafenib—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.47e-05	0.000545	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	6.45e-05	0.000543	CbGpPWpGaD
Vemurafenib—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.38e-05	0.000537	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	6.38e-05	0.000537	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PLB1—amyotrophic lateral sclerosis	6.29e-05	0.00053	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	6.28e-05	0.000529	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	6.28e-05	0.000529	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—TP53—amyotrophic lateral sclerosis	6.14e-05	0.000517	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	6.12e-05	0.000516	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	6.1e-05	0.000514	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	6.03e-05	0.000508	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.02e-05	0.000507	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	6.01e-05	0.000506	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	5.85e-05	0.000493	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	5.85e-05	0.000493	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GSR—amyotrophic lateral sclerosis	5.81e-05	0.000489	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CASP9—amyotrophic lateral sclerosis	5.79e-05	0.000488	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	5.76e-05	0.000485	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	5.74e-05	0.000483	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	5.67e-05	0.000478	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—FIG4—amyotrophic lateral sclerosis	5.66e-05	0.000477	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	5.6e-05	0.000472	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CST3—amyotrophic lateral sclerosis	5.51e-05	0.000464	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	5.5e-05	0.000463	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CST3—amyotrophic lateral sclerosis	5.46e-05	0.00046	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CHAT—amyotrophic lateral sclerosis	5.42e-05	0.000456	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	5.4e-05	0.000455	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	5.38e-05	0.000453	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	5.35e-05	0.000451	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—C3—amyotrophic lateral sclerosis	5.3e-05	0.000446	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	5.21e-05	0.000438	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—DAO—amyotrophic lateral sclerosis	5.12e-05	0.000431	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—C3—amyotrophic lateral sclerosis	5.09e-05	0.000429	CbGpPWpGaD
Vemurafenib—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.99e-05	0.00042	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.97e-05	0.000419	CbGpPWpGaD
Vemurafenib—BRAF—Disease—ERBB4—amyotrophic lateral sclerosis	4.96e-05	0.000417	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	4.96e-05	0.000417	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	4.96e-05	0.000417	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.94e-05	0.000416	CbGpPWpGaD
Vemurafenib—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.92e-05	0.000415	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	4.87e-05	0.00041	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—SQSTM1—amyotrophic lateral sclerosis	4.86e-05	0.000409	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CHAT—amyotrophic lateral sclerosis	4.77e-05	0.000402	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	4.73e-05	0.000398	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MMP9—amyotrophic lateral sclerosis	4.7e-05	0.000396	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	4.68e-05	0.000394	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	4.62e-05	0.000389	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.62e-05	0.000389	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	4.57e-05	0.000385	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ATF1—amyotrophic lateral sclerosis	4.56e-05	0.000384	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4.54e-05	0.000382	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	4.53e-05	0.000382	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—IGF1—amyotrophic lateral sclerosis	4.53e-05	0.000381	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CASP9—amyotrophic lateral sclerosis	4.34e-05	0.000365	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.26e-05	0.000359	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	4.23e-05	0.000356	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—VEGFA—amyotrophic lateral sclerosis	4.22e-05	0.000356	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.21e-05	0.000355	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.06e-05	0.000342	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CASP9—amyotrophic lateral sclerosis	4.01e-05	0.000337	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—SOD1—amyotrophic lateral sclerosis	4e-05	0.000337	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CASP9—amyotrophic lateral sclerosis	3.97e-05	0.000334	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	3.96e-05	0.000334	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PLB1—amyotrophic lateral sclerosis	3.88e-05	0.000327	CbGpPWpGaD
Vemurafenib—BRAF—Disease—APOE—amyotrophic lateral sclerosis	3.83e-05	0.000323	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	3.83e-05	0.000322	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	3.83e-05	0.000322	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.82e-05	0.000322	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ERBB4—amyotrophic lateral sclerosis	3.71e-05	0.000313	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	3.58e-05	0.000302	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	3.58e-05	0.000302	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSR—amyotrophic lateral sclerosis	3.58e-05	0.000302	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	3.5e-05	0.000295	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD40LG—amyotrophic lateral sclerosis	3.49e-05	0.000294	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.47e-05	0.000292	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ERBB4—amyotrophic lateral sclerosis	3.43e-05	0.000289	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ERBB4—amyotrophic lateral sclerosis	3.4e-05	0.000286	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.39e-05	0.000285	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	3.38e-05	0.000284	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	3.36e-05	0.000283	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.26e-05	0.000275	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.26e-05	0.000275	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.25e-05	0.000274	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	3.21e-05	0.00027	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.14e-05	0.000265	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	3.09e-05	0.00026	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—C3—amyotrophic lateral sclerosis	3.09e-05	0.00026	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	3.06e-05	0.000258	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	3.01e-05	0.000254	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	2.96e-05	0.000249	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	2.96e-05	0.000249	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.95e-05	0.000248	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CHAT—amyotrophic lateral sclerosis	2.94e-05	0.000248	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.91e-05	0.000245	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.88e-05	0.000243	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.81e-05	0.000236	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	2.77e-05	0.000233	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	2.72e-05	0.000229	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.68e-05	0.000226	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.68e-05	0.000226	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.68e-05	0.000225	CbGpPWpGaD
Vemurafenib—RAF1—Disease—APOE—amyotrophic lateral sclerosis	2.65e-05	0.000223	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—APOE—amyotrophic lateral sclerosis	2.63e-05	0.000221	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTGS2—amyotrophic lateral sclerosis	2.63e-05	0.000221	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.56e-05	0.000216	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	2.51e-05	0.000211	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IGF1—amyotrophic lateral sclerosis	2.44e-05	0.000205	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	2.43e-05	0.000205	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.4e-05	0.000202	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.36e-05	0.000198	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.28e-05	0.000192	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.26e-05	0.00019	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—amyotrophic lateral sclerosis	2.23e-05	0.000188	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.22e-05	0.000187	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—APOE—amyotrophic lateral sclerosis	2.2e-05	0.000185	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	2.1e-05	0.000177	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.06e-05	0.000173	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—C3—amyotrophic lateral sclerosis	2e-05	0.000168	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	1.94e-05	0.000163	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.93e-05	0.000163	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.88e-05	0.000158	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.86e-05	0.000156	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.84e-05	0.000155	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—amyotrophic lateral sclerosis	1.82e-05	0.000153	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—amyotrophic lateral sclerosis	1.8e-05	0.000152	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.71e-05	0.000144	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.61e-05	0.000136	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.59e-05	0.000134	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	1.59e-05	0.000134	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.58e-05	0.000133	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.53e-05	0.000129	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.51e-05	0.000127	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.45e-05	0.000122	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.45e-05	0.000122	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.33e-05	0.000112	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.31e-05	0.00011	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.29e-05	0.000108	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—amyotrophic lateral sclerosis	1.2e-05	0.000101	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.2e-05	0.000101	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOE—amyotrophic lateral sclerosis	1.2e-05	0.000101	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.18e-05	9.95e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.12e-05	9.4e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.11e-05	9.32e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.09e-05	9.22e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.02e-05	8.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1e-05	8.44e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	9.87e-06	8.31e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.54e-06	7.19e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	8.36e-06	7.04e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.19e-06	6.9e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.84e-06	6.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.58e-06	6.38e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.76e-06	5.7e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	6.45e-06	5.44e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.73e-06	4.83e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.42e-06	3.72e-05	CbGpPWpGaD
